Articles On Recce Pharmaceuticals (ASX:RCE)
Title | Source | Codes | Date |
---|---|---|---|
TMH Market Close: ASX200 edges higher as big four banks register gains
The ASX200 gradually climbed today to gain close to half a per cent. Financials registered the highest gains, up nearly 1.3 per cent With that, the big four banks NAB, CBA, Westpac and ANZ all gained around a per cent. Healthcare, on... |
themarketherald.com.au | RCE | 7 months ago |
Why is the Recce Pharmaceuticals share price collapsing 26% today?
The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from a trading halt and crashed deep into the red. In afternoon trade, the pharmaceutical company's shares are down 26% to 48 cents. Why is the Recce Pharmaceuticals share p... |
Motley Fool | RCE | 7 months ago |
Recce Pharmaceuticals (ASX:RCE) taps investors for up to $11m to drive anti-infective trials and US expansion
Recce Pharmaceuticals (RCE) is raising up to $11 million through a strongly supported placement and entitlement offer The placement comprises the issuance of 18.2 million new shares at 44 cents each Funds will be used toward further t... |
themarketherald.com.au | RCE | 7 months ago |
Closing Bell: Benchmark ends lower, loses 2.2% for the week. China jitters, I suppose. It’s unpleasant to report and I’m not proud.
ASX 200 closes about 0.3% lower, down well over 2.2% for the week. Materials and Consumer discretionary weigh, Healthcare rises. Small caps led by Oliver’s Real Foods, which has leapt mightily despite having no fresh news. The Aussie... |
Stockhead | RCE | 7 months ago |
TMH Market Update: Chevron strikes threaten global LNG supply
The ASX200 has traded down about point four of a per cent this morning. Sector performances varied, with utilities leading with a gain of .7 per cent, while materials stocks shed just shy of a per cent. Mining giants BHP, FMG and Ri... |
themarketherald.com.au | RCE | 7 months ago |
TMH Market Update: ASX slips, energy bucks the trend
The Australian stock market has dropped more than three-quarters of a per cent in the first hours of trade. Energy has been the only sector in the green after oil-producing nations vowed to continue limiting supply. Energy has been up we... |
themarketherald.com.au | RCE | 8 months ago |
ASX Health Stocks: Bod Science surges 20pc on cannabis trial results; Recce gets Vietnam trade mark
Cannabis biotech Bod surges after good clinical trial results Imricor granted US$1.15m award in the US Recce issued trademark registration in Vietnam Bod Science’s CBD-based insomnia drug beats placebo Cannabis focused biotech Bod Scien... |
Stockhead | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) secures RECCE trademark registration in Vietnam
Recce Pharmaceuticals (RCE) secures trademark registration for RECCE in Vietnam It was issued by the Intellectual Property Office of Vietnam Vietnam’s pharmaceutical market is expected to reach A$25.2 billion in value by 2026 Recce... |
themarketherald.com.au | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) successfully kills antibiotic-resistant bacteria in early stage gel trial
Recce Pharmaceuticals (RCE) reports its R327 gel product saw one elderly patient avoid amputation of an infected toe The company also cited two other patients with antibiotic-resistant infections who both responded well to the treatment... |
themarketherald.com.au | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial
Recce Pharmaceuticals (RCE) receives the green light to advance to the next cohort of its anti-infective R327 UTI phase I/II clinical trial The Independent Safety Committee agrees R327 is safe and well-tolerated at IV dosages of 2500mg,... |
themarketherald.com.au | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial
Recce Pharmaceuticals (RCE) kicks off its phase I/II diabetic foot infection trial The company will apply its flagship R327 anti-infective as a topical treatment RCE is using R327 to treat UTIs, burns patients, and now those with DF... |
themarketherald.com.au | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds
Recce Pharmaceuticals’ (RCE) phase I/II R327 topical burn wound clinical trial successfully treats bacterial infections in all patients to date Clinicians report a visible reduction in bacterial infections within the first 24 hours of us... |
themarketherald.com.au | RCE | 8 months ago |
TMH Spotlight: ASX edges higher as Woodside (ASX:WDS) agrees to sell 10pc Scarborough interest
The ASX has seen a slight lift, up almost 0.2 per cent in early afternoon trade. Materials are leading the sectors up around half a per cent, good news for those attending Diggers & Dealers in Kalgoorlie. The sector is followed cl... |
themarketherald.com.au | RCE | 8 months ago |
Mesoblast shares continue slide, but this ASX biotech stock is soaring 23%!
Mesoblast Ltd (ASX: MSB) shares are sliding again on Tuesday. Shares in the ASX biotech company are down 3.7% at time of writing to 40 cents a share. That puts Mesoblast shares down a painful 55% since the opening bell rang on 3 January.... |
Motley Fool | RCE | 8 months ago |
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
Recce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) program Race Oncology unveils new corporate strategy Recce surges on anecdotal results Recce Pharma (ASX:RCE) raced higher by more than 20%... |
Stockhead | RCE | 8 months ago |
Top 10 at 10: James Hardie delivers super strong quarter; Auris digs up more gold
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | RCE | 8 months ago |
Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections
Recce Pharmaceuticals (RCE) RCE 327 Gel shows promise in treating multiple antibiotic-resistant infections under the TGA SAS Category A The gel achieved a >99.99 per cent reduction against MRSA in an ex-vivo burn wound study Clinic... |
themarketherald.com.au | RCE | 8 months ago |
Recce Pharmaceuticals (ASX:RCE) wins Australian patent for anti-infectives
Recce Pharmaceuticals (RCE) is granted a new patent in Australia protecting its in-house R327 and R529 anti-infectives Recce is primarily focused on R327 which is the subject of an ongoing trial showing superior results so far compared... |
themarketherald.com.au | RCE | 9 months ago |
TMH Market Close: ASX ends week trading lower
The ASX200 closed 0.7 per cent down to finish the week. Only energy, IT and utilities sectors ended the week afloat, and then only just. Uncertainties around interest rates took a toll, exacerbated by fading hopes around China injecti... |
themarketherald.com.au | RCE | 9 months ago |
TMH Spotlight: Retail spending slumps to lowest levels in more than two years
The ASX 200 has been trading down almost a per cent – energy’s the only sector making gains and only just. Materials has been the worst performer shedding more than 1.8 per cent. Ahead of the RBA’s interest decision next week, the Bu... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) completes dosing in phase I/II R327 trial
Recce Pharmaceuticals’ (RCE) phase I/II trial partner has wrapped up the second-stage dosages of its ongoing trial A third cohort of patients is now being recruited ahead of schedule The company’s flagship anti-infective UTI product... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule
Recce Pharmaceutical’s (RCE) flagship anti-infective UTI treatment R327 was proven to be safe last week The company’s phase I/II trial is now accelerating ahead of schedule with the help of NSW-based partner Scientia Recce expects d... |
themarketherald.com.au | RCE | 9 months ago |
TMH Market Spotlight: ASX trades higher at midday
The ASX is trading well today up nearly half a per cent with only the materials and communications sectors taking a dip. ASX200 giant Woodside Energy (WDS) is up 1.5 per cent after releasing its June quarterly report. Its full-year produ... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial
Recce Pharmaceuticals (RCE) announces “positive” results from its completed phase one study of anti-infective R327 The trial doses R327 from 50mg to 6000mg and marks the first-in-human study to display safe and well-tolerated treatment w... |
themarketherald.com.au | RCE | 9 months ago |
TMH Spotlight: RBA’s Lowe hopes to retain top job as Treasurer’s decision looms
The Reserve Bank Governor Phillip Lowe would like to continue in the role he’s held since 2016. Speaking at the Australian Conference of Economists in Brisbane today, he recognised that Treasurer Jim Chalmers will reveal his decision on... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) receives $801k through R&D advance
Recce Pharmaceuticals (RCE) receives $801,604 from Radium Capital as part of Recce’s future research and development tax incentive The company is now over $3 million in rebates for its R&D activities through FY23 RCE CEO James Gr... |
themarketherald.com.au | RCE | 9 months ago |
First cohort dosed in RECCE 327 rapid infusion UTI clinical trial
Recce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R327 at faster infusion rates has successfully dosed its first cohort of male and female subjects. |
BiotechDispatch | RCE | 9 months ago |
TMH Spotlight: ASX200 continues gains in afternoon trade
The ASX 200 has dipped just a little in early trade. Exploration company Dreadnought Resources (DRE) is up more than five per cent after defining fresh rare earths’ zones at its Mangaroon project in Western Australia. A 24-hole, 4000-... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial
Recce Pharmaceuticals is developing an IV-administered treatment for Urinary Tract Infections (UTIs) Its RECCE 327 formula has been observed to rapidly kill E. coli bacteria in both male and female patients The company recently woun... |
themarketherald.com.au | RCE | 9 months ago |
Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327
Recce Pharmaceuticals (RCE) gains approval from the Human Research Ethics Committee to expand its phase I/II trial of R327 to treat UTIs The trial is assessing faster administration rates with Scientia Clinical Research facilitating the... |
themarketherald.com.au | RCE | 10 months ago |
TMH Spotlight: ASX200 tracks higher in midday trade
The ASX is tracking up in midday trade, with mining giants and the big four banks all in positive territory. In the materials space, Leo Lithium (LLL) has jumped 17.6 per cent after China’s largest lithium producer, Ganfeng, committed to... |
themarketherald.com.au | RCE | 11 months ago |
Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott
Recce Pharmaceuticals (RCE) appoints outpatient nurses from leading healthcare provider Ascott The nurses, trained in R327 DFI treatment, will broaden the company’s diabetic foot infection (DFI) trial patient population RCE’s phase on... |
themarketherald.com.au | RCE | 11 months ago |
TMH Spotlight: Siren Gold (ASX:SNG) intercepts high-grade gold in first Auld Creek drill hole, Western Yilgarn (ASX:WYX) defines “highly fertile” ultramafic belt
The ASX opened on a higher note today, with real estate, energy, and banking stocks contributing to the overall gain. The materials sector also led the pack, climbing nearly two per cent before lunchtime. Red 5 (RED) was amongst the comp... |
themarketherald.com.au | RCE | 11 months ago |
Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023
Recce Pharmaceuticals (RCE) secures sponsorship from the West Australian government to attend BIO Korea 2023 RCE has been selected as one of three WA companies to attend the bio-health industry conference in Seoul this week The govern... |
themarketherald.com.au | RCE | 11 months ago |
Recce Pharmaceuticals (ASX:RCE) makes headway against sepsis-causing superbugs
Developing a drug that is safe and effective for public use is no easy feat. It requires years of clinical trials, extensive research, and a significant financial investment before it can be sold on the shelves of your local pharmacy. Ma... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) receives ethics approval for phase I/II clinical trial of R327
Recce Pharmaceuticals (RCE) receives Human Research Ethics Committee (HREC) approval to start a phase I/II intravenous clinical trial of its lead R327 drug As part of the trial, RCE will assess intravenous doses of R327 at infusion rates... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) works to confirm efficacy of first breakthrough antibiotic in two decades
Recce Pharmaceuticals (RCE) last year confirmed the safety of its R327 antibiotics treatment for human use, and now it’s working to confirm the treatment’s efficacy in the patient population. R327 is the world’s first breakthrough antibi... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives
Recce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives The patent covers the “Process for Preparation of Biological... |
themarketherald.com.au | RCE | 1 year ago |
ASX Today: Stocks to watch on Tuesday
The ASX is tipped to open slightly higher on Tuesday following the slight rise to ASX futures when they traded during New York hours on Good Friday. That said, it is shaping up to be a big week for Wall Street, with key price data and qu... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals announces planned grant of 'Patent Family 4' for anti-infectives
Recce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued notification of intent to grant the first of its new 'Patent Family 4' for its anti-infectives 'Process for Preparation of Biologically Activ... |
BiotechDispatch | RCE | 1 year ago |
Market Highlights: Aussie becomes first to sue ChatGPT for defamation, and 5 ASX small caps to watch today
The ASX 200 will open slightly higher on Tuesday Tesla to expand in China to produce mega batteries Aussie Brian Hood sues ChatGPT for defamation The ASX is set for a modest opening on Tuesday after a mixed session in New York. At 8am A... |
Stockhead | RCE | 1 year ago |
TMH Spotlight: Energy stocks surge in early trade
Energy stocks have surged in early trade after OPEC’s controversial move to cut oil production by one million barrels per day. But it’s been a boost to companies in the sector, which has risen around 1.5 per cent. TMK Energy shares al... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) pockets further Radium funds through R&D advance
Recce Pharmaceuticals (RCE) pockets a further $973,144 from Radium Capital as part of Recce’s future research and development tax incentive The payment from Radium represents an accountant-verified proportion of Recce’s December to Febru... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals receives R&D advance from Radium Capital
Recce Pharmaceuticals (ASX:RCE) has received further non-dilutive funds from Radium Capital of almost $1 million as an advance payment of its R&D Tax Incentive rebate from the Australian government. |
BiotechDispatch | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial
Recce Pharmaceuticals (RCE) selects CMAX Clinical Research in South Australia as the independent facility for a clinical trial to treat urinary tract infections (UTIs) The phase one and two intravenous clinical trial will assess RCE’s le... |
themarketherald.com.au | RCE | 1 year ago |
ASX Health Stocks: HeraMED is traveling smoothly in the US; Recce names Adelaide firm to run Phase1/2 trial
HeraMED’s first commercial rollout in the US is progressing well Recce Pharma is set to commence Phase I/II clinical trial Maternity care medtech company, HeraMED (ASX:HMD), says the first phase of its commercial rollout in the US is pr... |
Stockhead | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) receives ‘RECCE’ trademark in Hong Kong
Recce Pharmaceuticals (RCE) receives ‘RECCE’ trademark from the Trade Marks Registry Intellectual Property Department in Hong Kong It bolsters the company’s IP portfolio, with issued patents and patent applications already in the biggest... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals (ASX:RCE) pockets $6.21m in R&D payments
Recce Pharmaceuticals (RCE) pockets a research and development (R&D) refund of $6.21 million The cash receipt comprises $4.3 million from the Australian Tax Office for the year ending June 30, 2022, and an advance payment of $1.9 mil... |
themarketherald.com.au | RCE | 1 year ago |
Recce Pharmaceuticals to Receive Australian Grant
Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world. The post Recce Pharmaceuticals to Receive Austral... |
MoneyMorning | RCE | 1 year ago |
ASX Close: Rally stalls ahead of inflation reports
The share market pared four days of gains following a mixed night on Wall Street as investors took some money off the table ahead of risk events later this week. The S&P/ASX 200 slid 20 points or 0.28 per cent to its first loss since... |
themarketherald.com.au | RCE | 1 year ago |